Literature DB >> 23828779

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Gregor Leibundgut1, Corey Scipione, Huiyong Yin, Matthias Schneider, Michael B Boffa, Simone Green, Xiaohong Yang, Edward Dennis, Joseph L Witztum, Marlys L Koschinsky, Sotirios Tsimikas.   

Abstract

Oxidized phospholipids (OxPLs) are present on apolipoprotein (a) [apo(a)] and lipoprotein (a) [Lp(a)] but the determinants influencing their binding are not known. The presence of OxPLs on apo(a)/Lp(a) was evaluated in plasma from healthy humans, apes, monkeys, apo(a)/Lp(a) transgenic mice, lysine binding site (LBS) mutant apo(a)/Lp(a) mice with Asp(55/57)→Ala(55/57) substitution of kringle (K)IV10)], and a variety of recombinant apo(a) [r-apo(a)] constructs. Using antibody E06, which binds the phosphocholine (PC) headgroup of OxPLs, Western and ELISA formats revealed that OxPLs were only present in apo(a) with an intact KIV10 LBS. Lipid extracts of purified human Lp(a) contained both E06- and nonE06-detectable OxPLs by tandem liquid chromatography-mass spectrometry (LC-MS/MS). Trypsin digestion of 17K r-apo(a) showed PC-containing OxPLs covalently bound to apo(a) fragments by LC-MS/MS that could be saponified by ammonium hydroxide. Interestingly, PC-containing OxPLs were also present in 17K r-apo(a) with Asp(57)→Ala(57) substitution in KIV10 that lacked E06 immunoreactivity. In conclusion, E06- and nonE06-detectable OxPLs are present in the lipid phase of Lp(a) and covalently bound to apo(a). E06 immunoreactivity, reflecting pro-inflammatory OxPLs accessible to the immune system, is strongly influenced by KIV10 LBS and is unique to human apo(a), which may explain Lp(a)'s pro-atherogenic potential.

Entities:  

Keywords:  kringles; lipoproteins; plasminogen

Mesh:

Substances:

Year:  2013        PMID: 23828779      PMCID: PMC3770094          DOI: 10.1194/jlr.M040733

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  62 in total

1.  Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells.

Authors:  M L Koschinsky; J E Tomlinson; T F Zioncheck; K Schwartz; D L Eaton; R M Lawn
Journal:  Biochemistry       Date:  1991-05-21       Impact factor: 3.162

2.  The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.

Authors:  Kiyohito Arai; May M Luke; Marlys L Koschinsky; Elizabeth R Miller; Clive R Pullinger; Joseph L Witztum; John P Kane; Sotirios Tsimikas
Journal:  Atherosclerosis       Date:  2009-10-12       Impact factor: 5.162

Review 3.  Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.

Authors:  Sebhat Erqou; Alexander Thompson; Emanuele Di Angelantonio; Danish Saleheen; Stephen Kaptoge; Santica Marcovina; John Danesh
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

4.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.

Authors:  J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

5.  Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.

Authors:  Sotirios Tsimikas; Ziad Mallat; Philippa J Talmud; John J P Kastelein; Nicholas J Wareham; Manjinder S Sandhu; Elizabeth R Miller; Joelle Benessiano; Alain Tedgui; Joseph L Witztum; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  J Am Coll Cardiol       Date:  2010-09-14       Impact factor: 24.094

6.  Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation.

Authors:  Longhou Fang; Richard Harkewicz; Karsten Hartvigsen; Philipp Wiesner; Soo-Ho Choi; Felicidad Almazan; Jennifer Pattison; Elena Deer; Tiffany Sayaphupha; Edward A Dennis; Joseph L Witztum; Sotirios Tsimikas; Yury I Miller
Journal:  J Biol Chem       Date:  2010-08-14       Impact factor: 5.157

7.  Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.

Authors:  Sotirios Tsimikas; Claes Bergmark; Reinaldo W Beyer; Raj Patel; Jennifer Pattison; Elizabeth Miller; Joseph Juliano; Joseph L Witztum
Journal:  J Am Coll Cardiol       Date:  2003-02-05       Impact factor: 24.094

8.  Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a).

Authors:  Celina Edelstein; Ditta Pfaffinger; Janet Hinman; Elizabeth Miller; Gregory Lipkind; Sotirios Tsimikas; Claes Bergmark; Godfrey S Getz; Joseph L Witztum; Angelo M Scanu
Journal:  J Biol Chem       Date:  2003-10-13       Impact factor: 5.157

9.  Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9-A resolution.

Authors:  A M Mulichak; A Tulinsky; K G Ravichandran
Journal:  Biochemistry       Date:  1991-10-29       Impact factor: 3.162

10.  Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.

Authors:  Sotirios Tsimikas; Herbert K Lau; Kyoo-Rok Han; Brian Shortal; Elizabeth R Miller; Amit Segev; Linda K Curtiss; Joseph L Witztum; Bradley H Strauss
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

View more
  56 in total

1.  Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Authors:  Corey A Scipione; Sera E Sayegh; Rocco Romagnuolo; Sotirios Tsimikas; Santica M Marcovina; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-10-16       Impact factor: 5.922

2.  Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

Authors:  Young Sup Byun; Jun-Hee Lee; Benoit J Arsenault; Xiaohong Yang; Weihang Bao; David DeMicco; Rachel Laskey; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

3.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

4.  Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report.

Authors:  Daniel S Hippe; Binh An P Phan; Jie Sun; Daniel A Isquith; Kevin D O'Brien; John R Crouse; Todd Anderson; John Huston; Santica M Marcovina; Thomas S Hatsukami; Chun Yuan; Xue-Qiao Zhao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-04       Impact factor: 8.311

5.  HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).

Authors:  Calvin Yeang; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-05-26       Impact factor: 5.922

6.  Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a).

Authors:  Ayelet Gonen; Xiaohong Yang; Calvin Yeang; Elena Alekseeva; Marlys Koschinsky; Joseph L Witztum; Michael Boffa; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2020-07-08       Impact factor: 5.922

7.  Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function.

Authors:  Jenny Sandmark; Anna Tigerström; Tomas Akerud; Magnus Althage; Thomas Antonsson; Stefan Blaho; Cristian Bodin; Jonas Boström; Yantao Chen; Anders Dahlén; Per-Olof Eriksson; Emma Evertsson; Tomas Fex; Ola Fjellström; David Gustafsson; Margareta Herslöf; Ryan Hicks; Emelie Jarkvist; Carina Johansson; Inge Kalies; Birgitta Karlsson Svalstedt; Fredrik Kartberg; Anne Legnehed; Sofia Martinsson; Andreas Moberg; Marianne Ridderström; Birgitta Rosengren; Alan Sabirsh; Anders Thelin; Johanna Vinblad; Annika U Wellner; Bingze Xu; Ann-Margret Östlund-Lindqvist; Wolfgang Knecht
Journal:  J Biol Chem       Date:  2020-03-04       Impact factor: 5.157

8.  Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

Authors:  Fleur M van der Valk; Siroon Bekkering; Jeffrey Kroon; Calvin Yeang; Jan Van den Bossche; Jaap D van Buul; Amir Ravandi; Aart J Nederveen; Hein J Verberne; Corey Scipione; Max Nieuwdorp; Leo A B Joosten; Mihai G Netea; Marlys L Koschinsky; Joseph L Witztum; Sotirios Tsimikas; Niels P Riksen; Erik S G Stroes
Journal:  Circulation       Date:  2016-08-05       Impact factor: 29.690

Review 9.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 10.  Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.

Authors:  Sotirios Tsimikas
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.